By the clinical cutoff date , 103 patients ( 20 % ) had died in the adjuvant capecitabine and oxaliplatin group versus 141 patients ( 27 % ) in the observation group ( stratified HR 066 , 95 % CI 051-085 ; p = 00015 ) .